Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Innovation Council · Running

FENM4PTSD Development of a novel class of therapeutics for PTSD treatment and other neurodegenerative disorders

Coordinator
Rest Therapeutics, France
Runs
1 May 2024 to 30 April 2026
Status
Running
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101144958

What the project is doing

In the project's own words, from its summary on CORDIS.

ReST Therapeutics is a French biotech company founded late 2020 that develops breakthrough therapies to treat complex central nervous system disorders, in particular, Post-Traumatic Stress Disorder (PTSD) under its various forms followed by Alzheimer Disease (AD). Our lead candidate - FENM is a novel and proprietary chemical entity (NCE) targeting specifically a subtype of NMDA receptor (involved in synaptic plasticity) in order to facilitate stress release and neuroprotection without triggering adverse side effects of current NMDA targeting drugs.

FENM will enter First-in-Human in June 2023 to initiate the clinical demonstration on PTSD. ReST is also advancing new compounds to generate a robust library of candidates and generalize its NMDAr subtype modulation platform with the potential to treat other neurologic disorders. With the EIC support, ReST will bring FENM to clinical PoC (PhIIb) by 2027, secure a partnership with a pharma company and develop new small molecules to expand its pipeline.

Topics

Who is involved

OrganisationCityCountryRole
Rest TherapeuticsParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI